FindTrial
Sign In

ZSP1273

DRUG9 trials

Sponsors

Guangdong Zhongsheng Pharmaceutical Co., Ltd., Guangdong Raynovent Biotech Co., Ltd

Conditions

Drug Drug InteractionDrug-drug InteractionElderHepatic ImpairmentInfluenzaInfluenza AInfluenza aKidney Impairment

Phase 1

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.
CompletedNCT03679143
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Influenza
Start: 2018-09-20End: 2019-04-26Updated: 2019-08-14
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
CompletedNCT05108051
Guangdong Raynovent Biotech Co., LtdDrug-drug Interaction
Start: 2020-11-19End: 2021-03-17Updated: 2021-11-04
Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment
CompletedNCT05856513
Guangdong Raynovent Biotech Co., LtdHepatic Impairment, Pharmacokinetics
Start: 2023-06-15End: 2023-07-04Updated: 2023-12-01
A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam
CompletedNCT05942365
Guangdong Raynovent Biotech Co., LtdDrug Drug Interaction, Midazolam, Warfarin
Start: 2023-06-25End: 2023-08-04Updated: 2023-12-06
Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid
CompletedNCT05954624
Guangdong Raynovent Biotech Co., LtdDrug Drug Interaction
Start: 2023-07-10End: 2023-11-30Updated: 2024-01-29
Pharmacokinetics of ZSP1273 in Elder Participants
CompletedNCT06157450
Guangdong Raynovent Biotech Co., LtdElder
Start: 2023-10-11End: 2023-11-17Updated: 2023-12-05
Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease
CompletedNCT06248567
Guangdong Raynovent Biotech Co., LtdKidney Impairment
Start: 2024-01-15End: 2024-05-30Updated: 2025-03-19

Phase 3

Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A
Active, not recruitingNCT07229820
Guangdong Raynovent Biotech Co., LtdInfluenza A
Start: 2025-11-08End: 2025-12-31Updated: 2025-12-16
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A
Active, not recruitingNCT07229807
Guangdong Raynovent Biotech Co., LtdInfluenza a
Start: 2025-11-22End: 2025-12-31Target: 119Updated: 2025-12-16

Related Papers

Pharmacokinetics, safety, and tolerability of onradivir in participants with severe renal impairment and matched healthy control participants
Antimicrobial Agents and Chemotherapy2025-08-041 citations
A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug–drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects
Antimicrobial Agents and Chemotherapy2025-02-245 citations
Single‐Dose Tolerability and Pharmacokinetics of Onradivir in Chinese Patients with Hepatic Impairment and Healthy Matched Controls
The Journal of Clinical Pharmacology2024-09-175 citations
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects
Expert Opinion on Investigational Drugs2021-10-1717 citations